Friday, September 29, 2023


Biotechnology News Magazine

Juxiang Xia Joins Sparx Therapeutics

Latest Posts

Airway Therapeutics Completes Dose Escalation in Phase 1b Trial of Zelpultide Alfa (AT-100) for Very Preterm Infants at Risk for Bronchopulmonary Dysplasia

Airway Therapeutics began recruiting patients on March 28, 2023, for daily treatment up to 7 days at the highest dose of zelpultide alfa (rhSP-D) following a Data Safety Monitoring Committee (DSMC) report of no safety concerns.

Roche introduces navify® Algorithm Suite, a digital library of medical algorithms that enhances clinical decision-making to optimise patient care

At the global HIMSS1 Conference, Roche showcases navify Algorithm Suite, a single platform offering clinicians access to medical algorithms generating insights to help improve care decisions.

PathO3Gen Solutions UVZone® Proven 99.9993% Effective Against Candida Auris: Shoes and Floors in Healthcare Facilities Should Be Addressed as Outbreak Continues

PathO3Gen Solutions’ multi-patented UVZone Shoe Sanitizing Stations, when placed in high-traffic and high-risk areas, enhance healthcare facility infection control measures, and may improve overall hospital biosafety.

Pharming announces the first commercial shipments of Joenja® (leniolisib) to patients in the U.S.

Under the terms of Pharming's 2019 exclusive license agreement with Novartis for leniolisib, the corresponding first commercial sale of Joenja® triggers a $10 million milestone payment by Pharming to Novartis.

Juxiang Xia, former Fosun veteran

Sparx Therapeutics, an emerging biopharmaceutical company specializing in developing multi-specific antibody and antibody-drug conjugate (ADC) drugs, today announced the appointment of Ms. Juxiang Xia, a former Fosun veteran, as the COO of Sparx Yangzhou. Ms. Xia brings in decades of experience in operation, infrastructure building, governmental affairs, and investing.

“We are very proud to welcome Ms. Juxiang Xia,” said Dr. Gui-Dong Zhu, CEO and founder of Sparx. “Juxiang is particularly suited to run a complex operation like the Sparx manufacturing site in Yangzhou. We hold a high standard in target selection, antibody design and optimization, but we are even more critically aware of the importance in developing and maintaining high standards in our manufacturing processes. It takes a special talent like Juxiang to take on this massive project within a very tight timeline.” The Yangzhou facility is projected to be in operation by the end of 2022.

Ms. Juxiang Xia said she is excited about the new challenge and the future of Sparx. “I was told that making new medicines is the most complex team sport on the face of the earth. To bring a new drug that the world has never seen takes years of effort by top experts in many fields. his is a very worthwhile cause and deserves all our efforts. As being new to the industry , I hope I can bring fresh perspectives and my experience in organizing resources on scale and raising and allocating capital. Hopefully governmental affairs will help  facilitate this process,” said Ms. Xia, “I believe in our discovery team, therapeutic strategy and pipeline of potential products. I am committed to building a large antibody  production site that meets the highest international standards. I will make sure we will not only manufacture Sparx therapeutics for clinical trials and commercial use in a timely manner, but will also become a preferred manufacturing collaborator for multinationals. We aim to be China’s Genentech.”

Latest Posts

Learn More




Our Sister Publication

Medical Device News Magazine